These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 376706)

  • 1. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. II. In vitro cytotoxicity of lymphoid cells against normal and malignant syngeneic cells and against normal allogeneic cells.
    Olsson L; Ebbesen P
    J Immunol; 1979 Mar; 122(3):781-6. PubMed ID: 376706
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. I. Treatment efficiency correlated to autoimmune reactivity.
    Olsson L; Ebbesen P
    J Immunol; 1979 Mar; 122(3):772-80. PubMed ID: 376705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological intervention in neoplasia.
    Weiss DW
    Johns Hopkins Med J Suppl; 1974; 3():131-56. PubMed ID: 4371312
    [No Abstract]   [Full Text] [Related]  

  • 4. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease.
    Mathé G; Weiner R; Pouillart P; Schwarzenberg L; Jasmin C; Schneider M; Hayat M; Amiel JL; de Vassal F; Rosenfeld C
    Natl Cancer Inst Monogr; 1973 Dec; 39():165-75. PubMed ID: 4595314
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprophylaxis and treatment of leukemia in AKR mice: repetitive use of BCG.
    Mardiney MR; Ungaro PC; Drake WP
    Natl Cancer Inst Monogr; 1973 Dec; 39():89-90. PubMed ID: 4595329
    [No Abstract]   [Full Text] [Related]  

  • 7. Young F mice spontaneously generate cytotoxic T cells against parental targets.
    Ishikawa H; Dutton RW
    J Immunol; 1979 Nov; 123(5):2034-9. PubMed ID: 314956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of antigens coded in murine leukemia viruses on thymocytes of allogeneic donor origin in AKR mice following syngeneic or allogeneic bone marrow transplantation.
    Wustrow TP; Good RA
    Cancer Res; 1985 Dec; 45(12 Pt 1):6428-35. PubMed ID: 2998600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies.
    Rosenstein M; Rosenberg SA
    J Natl Cancer Inst; 1984 May; 72(5):1161-5. PubMed ID: 6609266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated lymphoid cells: analysis of host cells that bind to syngeneic and allogeneic tumor cells shortly after tumor administration.
    Schick B; Berke B
    Transplant Proc; 1977 Mar; 9(1):1157-60. PubMed ID: 867485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity in vitro by products of specifically stimulated spleen cells: susceptibility of tumor cells and normal cells.
    Meltzer MS; Bartlett GL
    J Natl Cancer Inst; 1972 Nov; 49(5):1439-43. PubMed ID: 4568090
    [No Abstract]   [Full Text] [Related]  

  • 12. Specificity of cytolytic T cells directed against AKR/Gross virus-induced syngeneic leukemias: antibodies directed against H-2K, but not against viral proteins, inhibit lysis.
    Green WR; Nowinski RC; Henney CS
    J Immunol; 1980 Aug; 125(2):647-55. PubMed ID: 6156211
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy of human leukemia.
    Baker MA; Taub RN
    Mt Sinai J Med; 1972; 39(6):548-65. PubMed ID: 4565179
    [No Abstract]   [Full Text] [Related]  

  • 14. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
    Cheever MA; Greenberg PD; Fefer A
    Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCG immunization for the lymphoid leukemia line (LSTRA) in CDF1 mice.
    Chaparas SD; Chirigos M; Pearson J; Sher N
    Natl Cancer Inst Monogr; 1973 Dec; 39():87-8. PubMed ID: 4595328
    [No Abstract]   [Full Text] [Related]  

  • 17. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
    Braun DP; Mokyr MB; Dray S
    Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2.
    Cheever MA; Greenberg PD; Fefer A
    J Immunol; 1981 Apr; 126(4):1318-22. PubMed ID: 6970768
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
    Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
    Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of normal allogeneic responder cells in mouse mixed leukocyte culture by long-passage AKR leukemic lymphoblasts.
    Rodey GE; Sprader JC; Bortin MM
    Cancer Res; 1974 Jun; 34(6):1289-94. PubMed ID: 4275007
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.